Compliance monitoring of NSAID drug therapy in ankylosing spondylitis, experiences with an electronic monitoring device

Br J Rheumatol. 1996 Jan;35(1):60-5. doi: 10.1093/rheumatology/35.1.60.

Abstract

We concluded a randomized, controlled trial to compare once-daily 20 mg piroxicam versus once-daily 20 mg tenoxicam in ankylosing spondylitis. We recorded patients' dosing histories with electronic monitors for an average of 225 days (range 55-379) in 34 recipients of piroxicam and 31 recipients of tenoxicam. Dosing histories with the two agents were similar and are combined. Patients took 81% of prescribed doses; 78% once daily (as prescribed) and 3% as two or more daily doses. On 19% of all monitored days, there was no record of a dose being taken; 68% were single no-dose days, the rest (32%) being 2 to >10 consecutive no-dose days. In 3% of monitored days, extra doses were evidently taken, 88% as twice daily and 12% as three or more doses. Only 22% of all patients (14/65) strictly complied with the regimen: one dose daily every day. The remainder alternated between no-dose days and extra-dose days. We found no correlation between patient compliance and improvement in reported pain or morning stiffness.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*
  • Double-Blind Method
  • Drug Administration Schedule
  • Drug Monitoring / instrumentation
  • Humans
  • Patient Compliance*
  • Piroxicam / administration & dosage*
  • Piroxicam / analogs & derivatives*
  • Spondylitis, Ankylosing / drug therapy*
  • Time Factors
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Piroxicam
  • tenoxicam